Hence, since blocking the PD-L1 pathway is a potential scheme for HCC therapy, miR-378a-3p may be a promising novel target for the development of treatments targeting PD-L1-mediated immune response evasion. This evidence concerns the gene CD274 and hepatocellular carcinoma.